These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38053143)

  • 1. An integrative evaluation of circadian gene TIMELESS as a pan-cancer immunological and predictive biomarker.
    Yang Y; Tang X; Lin Z; Zheng T; Zhang S; Liu T; Yang X
    Eur J Med Res; 2023 Dec; 28(1):563. PubMed ID: 38053143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pan-cancer analysis identifies RNF43 as a prognostic, therapeutic and immunological biomarker.
    Xu Y; Lin Z; Ji Y; Zhang C; Tang X; Li C; Liu T
    Eur J Med Res; 2023 Oct; 28(1):438. PubMed ID: 37848933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of TIMELESS and RORA as key clock molecules of non-small cell lung cancer and the comprehensive analysis.
    Xian H; Li Y; Zou B; Chen Y; Yin H; Li X; Pan Y
    BMC Cancer; 2022 Jan; 22(1):107. PubMed ID: 35078435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pan-cancer analysis of ubiquitin-specific protease 7 and its expression changes in the carcinogenesis of scar ulcer].
    Zhang SY; Ruan JJ; Jin DM; Chen N; Xie WG; Ruan QF
    Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi; 2023 Jun; 39(6):518-526. PubMed ID: 37805766
    [No Abstract]   [Full Text] [Related]  

  • 5. Potential cancer-related role of circadian gene TIMELESS suggested by expression profiling and in vitro analyses.
    Mao Y; Fu A; Leaderer D; Zheng T; Chen K; Zhu Y
    BMC Cancer; 2013 Oct; 13():498. PubMed ID: 24161199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pan-cancer evidence of prognosis, immune infiltration, and immunotherapy efficacy for annexin family using multi-omics data.
    Shen C; Zhang S; Zhang Z; Yang S; Zhang Y; Lin Y; Fu C; Li Z; Wu Z; Wang Z; Li Z; Guo J; Li P; Hu H
    Funct Integr Genomics; 2023 Jun; 23(3):211. PubMed ID: 37358720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
    Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
    Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and immunological characteristics of TGM3 in pan-cancer: A potential prognostic biomarker.
    Zhang W; Wu C; Zhou K; Cao Y; Zhou W; Zhang X; Deng D
    Front Genet; 2022; 13():993438. PubMed ID: 36685895
    [No Abstract]   [Full Text] [Related]  

  • 9. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LncRNA WAC-AS1 expression in human tumors correlates with immune infiltration and affects prognosis.
    Wang Y; Gong H; Cao Y
    Hereditas; 2023 May; 160(1):26. PubMed ID: 37248547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker.
    Cheng X; Wang X; Nie K; Cheng L; Zhang Z; Hu Y; Peng W
    Front Immunol; 2021; 12():646523. PubMed ID: 33679809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RecQ mediated genome instability 2 (
    Wei W; Ying X; Chen L; Sun Q; Lu X; Xia Y; Xu R; Zhu Z; Zhang D; Tang Q; Li L; Xie J; Yu H
    Aging (Albany NY); 2022 May; 14(9):4107-4136. PubMed ID: 35552266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pan-cancer analyses reveal IGSF10 as an immunological and prognostic biomarker.
    Zhou Y; Gao M; Jing Y; Wang X
    Front Genet; 2022; 13():1032382. PubMed ID: 36685968
    [No Abstract]   [Full Text] [Related]  

  • 14. Aberrant TIMELESS expression is associated with poor clinical survival and lymph node metastasis in early-stage cervical carcinoma.
    Zhang W; He W; Shi Y; Zhao J; Liu S; Zhang F; Yang J; Xie C; Zhang Y
    Int J Oncol; 2017 Jan; 50(1):173-184. PubMed ID: 27909716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic and Immunological Roles of MMP-9 in Pan-Cancer.
    Zeng Y; Gao M; Lin D; Du G; Cai Y
    Biomed Res Int; 2022; 2022():2592962. PubMed ID: 35178444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PTPN1 is a prognostic biomarker related to cancer immunity and drug sensitivity: from pan-cancer analysis to validation in breast cancer.
    Zhao R; Chen S; Cui W; Xie C; Zhang A; Yang L; Dong H
    Front Immunol; 2023; 14():1232047. PubMed ID: 37936713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ARPC2: A Pan-Cancer Prognostic and Immunological Biomarker That Promotes Hepatocellular Carcinoma Cell Proliferation and Invasion.
    Huang S; Dong C; Li D; Xu Y; Wu J
    Front Cell Dev Biol; 2022; 10():896080. PubMed ID: 35733852
    [No Abstract]   [Full Text] [Related]  

  • 18. Insights into the Oncogenic, Prognostic, and Immunological Role of BRIP1 in Pan-Cancer: A Comprehensive Data-Mining-Based Study.
    Liu Y; Wu X; Feng Y; Jiang Q; Zhang S; Wang Q; Yang A
    J Oncol; 2023; 2023():4104639. PubMed ID: 37153833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pan-Cancer Analysis of the N6-Methyladenosine Eraser FTO as a Potential Prognostic and Immunological Biomarker.
    Zhao C; Liu Y; Ju S; Wang X
    Int J Gen Med; 2021; 14():7411-7422. PubMed ID: 34744452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value and immunological role of PDCD1 gene in pan-cancer.
    Miao Y; Wang J; Li Q; Quan W; Wang Y; Li C; Wu J; Mi D
    Int Immunopharmacol; 2020 Dec; 89(Pt B):107080. PubMed ID: 33069926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.